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from eight managed care organizations. Index claims were out-
patient or emergency department visits in 1999–2001 by indi-
viduals aged 25–64 with a primary diagnosis of pneumonia,
antibiotic prescription within three-days, chest x-ray on index
date, continuous enrollment for 12-months prior, 30-days after
index visit. Exclusion criteria: antibiotic prescription, pneumo-
nia diagnosis, or hospitalization in prior 30-days; initial therapy
with multiple antibiotics; in prior 12-months residence in a 
long-term care facility or diagnosis of lung cancer, secondary
malignancy, HIV/AIDS, cystic ﬁbrosis, immunodeﬁciency. 
We considered the following comorbid illnesses: chronic liver, 
renal or lung disease; cerebrovascular disease; cardiac disease;
diabetes mellitus; malignancy. Follow-up claims were considered
CAP-related if the primary diagnosis, using the Clinical 
Classiﬁcations Software, was pneumonia; septicemia; pleurisy,
pneumothorax or pulmonary collapse; respiratory failure, insuf-
ﬁciency or arrest; other lower respiratory infection. RESULTS:
In total, 5748 cases met criteria; 79.7% had no comorbidities,
16.8% had one comorbidity, and 3.5% had two or more comor-
bidities. Mean total charges were $955.97: 48.2% inpatient,
25.2% outpatient, 13.4% outpatient testing and diagnostics,
7.5% antibiotic prescriptions, 5.8% emergency department,
13.9% presenting to the emergency department had initial mean
charges of $360.48 compared with mean initial charges for out-
patients of $167.89. In total, 50.0% utilized follow-up services
with 3.0% requiring hospitalization. Mean total charges for
those eventually hospitalized were $16,436.23 compared with
$673.71 for the 13.1% of patients who failed initial treatment
but were not hospitalized, and $431.91 for the 78.0% of patients
requiring no additional antibiotics. Number of comorbidities
was strongly associated (p < 0.0001) with charges: $888.19 for
those without comorbidities vs. $1734.37 for those with multi-
ple comorbidities. CONCLUSION: Cost of outpatient CAP for
non-elderly adults is large even for those without comorbid
illness.
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OBJECTIVES: To determine the additional costs and lengths of
stay (LOS) attributable to complicated skin and soft tissue infec-
tions (cSSI) for patients admitted to Thomas Jefferson University
Hospital, an urban academic tertiary care hospital. METHODS:
All patients admitted between January 1, 2003 and December
31, 2003 were identiﬁed using the hospital billing system.
Patients with a potential cSSI were identiﬁed using the speciﬁc
ICD-9 diagnosis codes. Costs of care and lengths of stay, based
on the hospital’s true cost accounting system, were compared by
Diagnosis Related Group (DRG) between the cSSI population
and the non-cSSI population. RESULTS: Of the 33,764 patient
discharges in 2003, 1,883 (5.5%) included one of the cSSI diag-
nosis codes; these encompassed 225 DRGs. The mean cost for
cSSI cases was $20,965 higher than for non-cSSI cases, and mean
LOS was ten days higher for cSSI cases. For surgical and medical
DRGs, mean cost of cSSI added $42,563 onto the cost for cases
in surgical DRGs compared to an average increase of $10,048
added to cost of medical DRGs. Differences in costs and LOS
were observed in analyses by Major Disease Categories (MDCs)
and individual DRGs as well. For MDCs, myeloproliferative dis-
orders, multiple trauma, and diseases of the nervous system,
costs were $68,027, $48,286, and $27,496, higher for the cSSI
cases, respectively. This difference was also reﬂected in additional
days of stay of 22, 11, and 14 days, respectively. For patients
with cSSI, the three speciﬁc DRGs responsible for the maximum
total health care dollars expended were bone marrow trans-
plants, rehabilitation, and small and large bowel procedures.
CONCLUSIONS: cSSIs signiﬁcantly increase hospital resource
consumption and costs. The difference in costs is especially pro-
nounced for patients undergoing surgical procedures. Results
suggest that measures taken to avoid or more effectively treat
cSSIs could yield signiﬁcant savings to hospitals.
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OBJECTIVE: To estimate cost-utility of the following alterna-
tives in the treatment of chronic hepatitis C (CHC) in the
Mexican Institute of Social Security (IMSS): peginterferon,
peginterferon plus ribavirin, peginterferon plus ribavirin plus
thymosin alpha-1 and ﬁnally, not using any drug. METHODS:
In Mexico, more that one million persons are infected with CHC
virus and 80% of them develop chronic infection that might lead
to hepatic cirrhosis and other complications that affect quality
of life and costs of health care institutions. Cost-utility analysis
was carried out using institutional perspective and time horizon
of 45 years, discount rate of 3% for both, costs and effective-
ness. The base case was a 30-year-old man with CHC without
hepatic cirrhosis or cancer and cost and effectiveness data were
taken from literature, a Mexican expert panel and an on-going
clinical trial, not yet reported. Effectiveness data are reported in
QALYs and costs in 2004 USD. A decision tree using a Bayesian
approach and a Markov model were developed. Sensitivity
analysis was univariate, bivariate, threshold and probabilistic.
Acceptability curves and health net beneﬁts were estimated.
RESULTS: Triple therapy (peginterferon plus ribavirin plus thy-
mosin alpha-1) was dominant over the rest of alternatives costing
$1802 per QALY, while peginterferon plus ribavirin $2275 per
QALY and peginterferon only $2927 per QALY. Not using any
drug was the most costly alternative with $4201 per QALY. Sen-
sitivity analysis conﬁrmed the strength of the base study. Triple
therapy was not dominated in any comparative case. CON-
CLUSIONS: Triple therapy had the best cost-utility ratio and not
using any drug was the opposite, most expensive and with less
utility than all the compared alternatives. Although triple
therapy is initially very expensive, it provides the highest gains
in the long run, both in the improvement of quality of life and
in saving costs.
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OBJECTIVES: This study investigated the effect of using differ-
ent utilities for a cost-utility analysis comparing peginterferon
alpha-2b plus ribavirin, interferon alpha-2b plus ribavirin, and
no treatment for chronic hepatitis C from a U.S. payer’s per-
spective. METHODS: A Markov model was developed to sim-
ulate the lifetime disease progression of hepatitis C virus (HCV)
for a 45-year-old male. The analysis was conducted by stratify-
ing HCV genotypes. Health-state utilities were obtained from
previously published literature. Standard gamble patient-elicited
utilities were used as the base case. Five other expert-estimated
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utilities were compared to the patient-derived utilities. Treatment
data, disease transition probabilities, and hepatitis C related
costs were obtained from published literature. The costs of
hepatitis C treatments were obtained from an Internet pharmacy.
All costs were adjusted to 2004 USD. RESULTS: When patient-
reported utilities were used for HCV genotype 1, peginterferon
gained 1.28 additional quality-adjusted life years (QALYs) com-
pared with no treatment. The QALYs ranged from 0.71 to 2.35
when expert panel-estimated utilities were employed. For HCV
genotype 2 or 3 patients, peginterferon group had 2.72 more
QALYs than no treatment using patient-reported utilities. When
expert panel utilities were used for genotype 2 or 3, peginter-
feron had 1.61 to 4.85 additional QALYs than no treatment.
Using patient-derived utilities, the expected costs per QALY for
HCV genotype 1 receiving peginterferon and interferon treat-
ment were $2439 and $2335, respectively. For genotype 2 or 3,
these costs were $1152 and $1085 per QALY, respectively. The
lifetime HCV related cost for patients received no treatment was
$1975 per QALY regardless of HCV genotype. CONCLUSION:
Many expert panel-estimated utilities provided higher estimates
of the beneﬁts, and thus lower cost per QALY, for HCV treat-
ments as compared to patient-reported utilities.
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For patients with chronic hepatitis B, emergence of lamivudine
resistance is associated with poor clinical outcomes, more rapid
disease progression and poor quality of life. The clinical impli-
cations of lamivudune resistance are well described but the
health care costs are not. OBJECTIVE: The objective of this
study was to evaluate the health care utilization and direct
medical cost within the ﬁrst year of developing a lamivudine
refractory infection in chronic hepatitis B (CHB) patients.
METHODS: Physician estimates of health care utilization for the
care of lamivudine refractory CHB patients were collected in 
a survey of physicians treating CHB patients in the US. A 
questionnaire was mailed to 165 physicians of which 51
responded. Data on health care utilization was computed for
each health care cost category (Physician visits, hospitalizations,
diagnostic tests and radiological examinations). Unit costs were
derived based on the Medicare Physician Fee Schedule for pro-
cedures, the 2002 Health Care Cost and Utilization Project data-
base for inpatient hospitalization costs, and average wholesale
prices for medication costs. RESULTS: The total non-drug, direct
medical cost within the ﬁrst year of developing a lamivudine
refractory infection in a CHB patient was estimated at $2925.
Among the different cost categories diagnostic tests and special-
ist visits were the major cost drivers, accounting for an estimated
45% and 41% of the overall cost, respectively. Seventy four
percent of the patients were estimated to require a specialist visit.
Only 2% of patients were estimated to require a hospitalization
accounting for a negligible proportion of the costs. CONCLU-
SION: The estimated non-drug costs for patients refractory to
lamivudine represent a substantial economic burden. In addition,
the additional costs of rescue therapy further increase the cost
impact and make it considerably higher than the annual direct
medical cost for CHB patients who do not develop viral 
resistance.
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OBJECTIVES: To analyse the utilisation of antibiotics within the
Slovak Republic between 1992 and 2003. Adherence to princi-
ples of antibiotic policy lead to fundamental short and long term
ﬁnancial savings within health care systems. METHODS: For
1992–2003, the data of systemic antibiotic use for ambulatory
care, aggregated at the level of the active substance, were col-
lected, in accordance with the Anatomic Therapeutic Chemical
(ATC) classiﬁcation and Deﬁned Daily Dose (DDD) measure-
ment unit (WHO). Data of wholesalers, who are legally obliged
provide this information to the Slovak Institute for Drug
Control, was used for this detailed analysis of the Slovak con-
sumption of antibiotics. RESULTS: Long term analysis shows
that the antibiotic consumption had been increasing in human
medicine within Slovakia. In 1992 the consumption of antibi-
otics at the level of 19.4 DDD/1000/day increased to 28.0
DDD/1000/day in 1999. This analysis focused on the situation
in antibiotic consumption in 2001 and 2003 in more detail. The
results show that in 2003 as opposed to 2001, the consumption
of antibiotics decreased by 900,000 packages. In ﬁnancial ﬁgures
can be noticed a increase by 1.75 €mill., because the average
price for one package of antibiotics was at the level of 4.84€ in
2001 but in 2003 the price increased to a level of 5.64€. From
our analysis a signiﬁcant increase in the ATB consumption
expressed by DDD/1000/day can be seen (In 2001 it was 25.78
but in 2003 we can see the consumption 26.95 DDD/1000/day).
CONCLUSIONS: Inseparable components of the Slovak antibi-
otic policy must be viewed realistically with regard to the 
consumption of antibiotics and resistance. Antibiotic resistance
is a major public health problem, and antibiotic use is 
increasingly recognised as the major selective pressure driving
this resistance.
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OBJECTIVES: Several studies show that in developing countries,
low–income patients use low price counterfeit drugs provided by
the illegal drug market. In Cameroon, those false drugs repre-
sent 40% of the street market and lead to malaria therapeutic
failure and inappropriate medical expenses. The Yaoundé
program aims to improve access to efﬁcient antimalarial drugs
by providing a differentiated price policy through the ofﬁcial
private pharmacy distribution sector,allowing access to efﬁcient
antimalarials to low–income population which would otherwise
use street market drugs. METHODS: In 31 retail pharmacies of
Yaoundé, artesunate (Arsumax®)was made available at a “no
proﬁt no loss” public price of 1170FCFA (1.78€) instead of
3400FCFA (5.8€), ie: -66%. Eligibility of patients was based on
income below the poverty level (established by the Ministry of
Economy as 30€ monthly households incomes per number of
dependences).Program effectiveness was assessed by evaluating
the number of new patients having access to this lower price
Arsumax®. RESULTS: After 6 months of implementation,
